These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37521452)

  • 21. Oncological impact of cystoscopic findings in non-muscle-invasive bladder cancer: a meta-analysis.
    Yanagisawa T; Quhal F; Kawada T; Mostafaei H; Motlagh RS; Laukhtina E; Rajwa P; von Deimling M; Bianchi A; Pallauf M; Majdoub M; Pradere B; Abufaraj M; Moschini M; Karakiewicz PI; Iwatani K; Miki J; Kimura T; Shariat SF
    BJU Int; 2023 Jun; 131(6):643-659. PubMed ID: 36479820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes.
    Tan WS; Grajales V; Contieri R; Hensley P; Bree K; Msaouel P; Guo CC; Nogueras-Gonzalez GM; Navai N; Dinney CP; Kamat AM
    Eur Urol Open Sci; 2023 Jul; 53():16-22. PubMed ID: 37441349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?
    Park J; Song C; Shin E; Hong JH; Kim CS; Ahn H
    Urol Oncol; 2013 Aug; 31(6):849-56. PubMed ID: 21782482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials.
    Fernandez-Gomez J; Solsona E; Unda M; Martinez-Piñeiro L; Gonzalez M; Hernandez R; Madero R; Ojea A; Pertusa C; Rodriguez-Molina J; Camacho JE; Isorna S; Rabadan M; Astobieta A; Montesinos M; Muntañola P; Gimeno A; Blas M; Martinez-Piñeiro JA;
    Eur Urol; 2008 May; 53(5):992-1001. PubMed ID: 17950987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravesical gemcitabine for non-muscle invasive bladder cancer.
    Jones G; Cleves A; Wilt TJ; Mason M; Kynaston HG; Shelley M
    Cochrane Database Syst Rev; 2012 Jan; 1():CD009294. PubMed ID: 22259002
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of carcinoma in situ on the outcome of intravesical Bacillus Calmette-Guérin therapy for non-muscle-invasive bladder cancer: a comparative analysis of large real-world data.
    Tomida R; Miyake M; Minato R; Sawada Y; Matsumura M; Iida K; Hori S; Fukui S; Ohyama C; Miyake H; Hongo F; Taoka R; Kobayashi T; Kojima T; Matsui Y; Nishiyama N; Kitamura H; Nishiyama H; Fujimoto K; Hashine K;
    Int J Clin Oncol; 2022 May; 27(5):958-968. PubMed ID: 35142962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravesical docetaxel for high-risk non-muscle invasive bladder cancer after Bacillus Calmette-Guérin failure.
    Shantharam G; Amin A; Pereira J; Kott O; Mueller-Leonhard C; Mega A; Golijanin D; Gershman B
    Curr Urol; 2021 Mar; 15(1):33-38. PubMed ID: 34084119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mixed low- and high-grade non-muscle-invasive bladder cancer: a histological subtype with favorable outcome.
    Schubert T; Danzig MR; Kotamarti S; Ghandour RA; Lascano D; Dubow BP; Decastro GJ; Benson MC; McKiernan JM
    World J Urol; 2015 Jun; 33(6):847-52. PubMed ID: 25149472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The comparison of different BCG strains in the intravesical treatment of non-muscle invasive urothelial carcinoma of urinary bladder-A real-world practice.
    Chen YK; Huang EY; Chang YH; Kuo JY; Chung HJ; Wu HH; Lin TP; Lin CC; Fan YH; Huang IS; Lin ATL; Huang WJ
    J Chin Med Assoc; 2022 Sep; 85(9):928-934. PubMed ID: 36150105
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is Repeat Transurethral Resection Always Needed in High-Grade T1 Bladder Cancer?
    Calò B; Chirico M; Fortunato F; Sanguedolce F; Carvalho-Dias E; Autorino R; Carrieri G; Cormio L
    Front Oncol; 2019; 9():465. PubMed ID: 31214506
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hyperthermic Intravesical Chemotherapy (HIVEC) Using Epirubicin in an Optimized Setting in Patients with NMIBC Recurrence after Failed BCG Therapy.
    Blanc J; Ruggiero J; Lucca I; Arnold N; Kiss B; Roth B
    Cancers (Basel); 2024 Apr; 16(7):. PubMed ID: 38611077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy.
    Aydin AM; Baydar DE; Hazir B; Babaoglu B; Bilen CY
    World J Urol; 2020 Oct; 38(10):2537-2545. PubMed ID: 31900581
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancer.
    Daniels MJ; Barry E; Schoenberg M; Lamm DL; Bivalacqua TJ; Sankin A; Kates M
    Urol Oncol; 2020 Jan; 38(1):5.e9-5.e16. PubMed ID: 31255541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
    Shepherd AR; Shepherd E; Brook NR
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
    Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
    Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer.
    Ferro M; Barone B; Crocetto F; Lucarelli G; Busetto GM; Del Giudice F; Maggi M; Crocerossa F; Cantiello F; Damiano R; Borghesi M; Bove PL; Papalia R; Mari A; Luzzago S; Soria F; Marchioni M; La Civita E; Terracciano D; Mistretta FA; Piccinelli M; Marmiroli A; Russo GI; Schips L; Hurle R; Contieri R; Perdonà S; Del Prete P; Mirone V; Tataru OS; Musi G; Montanari E; de Cobelli O; Vartolomei MD
    Urol Oncol; 2022 Nov; 40(11):490.e13-490.e20. PubMed ID: 35676172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Compared Efficacy of Adjuvant Intravesical BCG-TICE vs. BCG-RIVM for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): A Propensity Score Matched Analysis.
    Del Giudice F; Flammia RS; Chung BI; Moschini M; Pradere B; Mari A; Soria F; Albisinni S; Krajewski W; Szydełko T; Laukhtina E; D'Andrea D; Gallioli A; Mertens LS; Maggi M; Sciarra A; Salciccia S; Ferro M; Scornajenghi CM; Asero V; Cattarino S; De Angelis M; Cacciamani GE; Autorino R; Pandolfo SD; Falagario UG; D'Altilia N; Mancini V; Chirico M; Cinelli F; Bettocchi C; Cormio L; Carrieri G; De Berardinis E; Busetto GM; On Behalf Of European Association Of Urology Eau-Young Academic Urologists Yau Urothelial Cancer Working Party
    Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative Effectiveness of Intravesical BCG-Tice and BCG-Moreau in Patients With Non-muscle-invasive Bladder Cancer.
    D'Andrea D; Soria F; Abufaraj M; Pones M; Gontero P; Machado AT; Waksman R; Enikeev DV; Glybochko PV; Adonias SP; Nahas WC; Shariat SF; Chade DC
    Clin Genitourin Cancer; 2020 Feb; 18(1):20-25.e2. PubMed ID: 31786120
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic Factors for Recurrence and Progression in Korean Non-Muscle-Invasive Bladder Cancer Patients: A Retrospective, Multi-Institutional Study.
    Kim HS; Ku JH; Kim SJ; Hong SJ; Hong SH; Kim HS; Kwon TG; Cho JS; Jeon SS; Joo KJ; Ahn HJ; Park HS; Seong do H; Kwon DD; Kim HJ; Lim JS; Lee HL
    Yonsei Med J; 2016 Jul; 57(4):855-64. PubMed ID: 27189277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design.
    Mmeje CO; Guo CC; Shah JB; Navai N; Grossman HB; Dinney CP; Kamat AM
    Eur Urol; 2016 Nov; 70(5):778-785. PubMed ID: 26922408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.